All In Biotech

NDA 017398 · Sandoz

Regonol

Pyridostigmine Bromide · Injection

Last checked: Nov 19, 2026Latest source record: Apr 5, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1973

Aug 14, 1973

Approved uses

1

Original approval plus efficacy supplements

Registered trials

45

6 Phase 3, 6 recruiting

FAERS reports

1,915

1,330 serious, 177 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 1, 2021.

INDICATIONS AND USAGE REGONOL ® (pyridostigmine bromide injection, USP) is indicated as a reversal agent or antagonist to the neuromuscular blocking effects of nondepolarizing muscle relaxants.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 14, 1973 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • REGONOL · PYRIDOSTIGMINE BROMIDE 5MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Pyridostigmine" as an intervention, any sponsor and status, largest first.

All 45 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myasthenia gravis192
  • fatigue165
  • dyspnoea147
  • drug ineffective145
  • off label use130
  • asthenia122
  • headache115
  • diarrhoea114
  • nausea96
  • malaise90
  • dizziness76
  • fall72

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
200516
200618
200719
200845
200948
201037
201153
201245
201315
201425
201550
201687
201780
2018104
201980
2020128
2021129
2022110
2023177
2024240
2025241
2026158

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Regonol (Pyridostigmine Bromide)

2024 spending

$45K

Beneficiaries

n/a

14 claims

Per beneficiary

n/a

$16.48 per unit

View as table
YearSpending
2020$39,521
2021$56,966
2022$45,500
2023$42,061
2024$44,823

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 233 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.